Poorer survival in obese colorectal cancer patients possibly linked to lower chemotherapy doses
Autistic individuals more likely to use recreational drugs to self-medicate
1 July 2021Myanmar orders 2 million to stay home as COVID-19 cases spike
2 July 2021Poorer survival in obese colorectal cancer patients possibly linked to lower chemotherapy doses
Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy, relative to their body surface area (BSA), than non-obese patients, show results from a large meta-analysis reported at the ESMO World Congress on Gastrointestinal Cancer 2021. Further findings showed that cumulative relative chemotherapy dose was associated with survival so may explain the poorer survival that has been seen in obese patients receiving adjuvant chemotherapy for colorectal cancer.
